Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Fosdenopterin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 682,766Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sentynl Therapeutics: Clinical Evidence for Nulibry in Molybdenum
    Sentynl Therapeutics: Clinical Evidence for Nulibry in Molybdenum

    04 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250404171911/en/Sentynl-Therapeutics-Announces-First-Comprehensive-Body-of-Clinical-Evidence-Supporting-NULIBRY-fosdenopterin-in-Treating-Molybdenum-Cofactor-Deficiency-Type-A-Compared-to-Natural-History

    BUSINESSWIRE
    04 Apr 2025
    Share Share
    UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A
    UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A

    18 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168581&sid=2

    PHARMABIZ
    18 Apr 2024
    Share Share
    Sentynl's NULIBRY® Authorized For MoCD Type A In UK
    Sentynl's NULIBRY® Authorized For MoCD Type A In UK

    16 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-receives-mhra-authorization-of-nulibry-fosdenopterin-for-treatment-of-mocd-type-a-in-great-britain-302117194.html

    PR NEWSWIRE
    16 Apr 2024
    Share Share
    Sentynl Announces Presentation of Study Evaluating the Safety of NULIBRY
    Sentynl Announces Presentation of Study Evaluating the Safety of NULIBRY

    07 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-presentation-of-study-evaluating-the-efficacy-and-safety-of-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a-at-2023-ssiem-annual-symposium-301920794.html

    PR NEWSWIRE
    07 Sep 2023
    Share Share
    Comharsa's Nulibry (Fosdenopterin) Receives Approval in Europe
    Comharsa's Nulibry (Fosdenopterin) Receives Approval in Europe

    30 Sep 2022

    // EMA

    https://www.pharmacompass.com/pdf/news/comharsas-nulibry-fosdenopterin-receives-approval-in-europe-28956.pdf

    EMA
    30 Sep 2022
    Share Share
    BridgeBio Pharma and Sentynl Receive Marketing Authorization NULIBRY®
    BridgeBio Pharma and Sentynl Receive Marketing Authorization NULIBRY®

    20 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/20/2519096/0/en/BridgeBio-Pharma-and-Sentynl-Therapeutics-Receive-Marketing-Authorization-in-the-EU-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html

    GLOBENEWSWIRE
    20 Sep 2022
    Share Share